Scythian Acquisition Target Colcanna Gains Colombia Cannabis Licensing

0
15

Colcanna SAS to receive production quota from Colombian Government TORONTO, July 09, 2018 (GLOBE NEWSWIRE) — Scythian Biosciences Corp. (the “Company” or “Scythian”) (TSXV:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) is pleased to announce that Colombian-based Colcanna SAS (“Colcanna”), the pending acquisition by Scythian, has received additional licences by the Ministry of Health for the extraction, production and research for the local market and export to international markets of  cannabis derivatives. The receipt of these licences is a significant step forward in the closure of our acquisition of Colcanna. We look forward to focusing our efforts on providing both the domestic and international market with access to pure, high grade medical Cannabis grown in the ideal conditions of the Colombia Coffee Zone. Colcanna is the only cultivator to receive a licence to cultivate Cannabis in the coveted Colombian coffee zone. Scythian previously announced on April 9, 2018, that it had entered into a binding letter of intent (“LOI”) to acquire MMJ Colombia Partners Inc. Scythian Acquisition Target Colcanna Gains Colombia Cannabis Licensing

thumbnail courtesy of newcannabisventures.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here